CADTH: *Health Technology Assessment*

2018 CANM-CAMRT JOINT ANNUAL CONFERENCE

Harindra Wijeysundera MD PhD FRCPC
Vice President Medical Devices & Clinical Interventions, CADTH
Associate Professor, Department of Medicine, & Institute for Health Policy, Management and Evaluation (iHPME) University of Toronto
Interventional Cardiologist, Schulich Heart Center, Sunnybrook Health Sciences Center
Scientist, Sunnybrook Research Institute

CADTH

CANM
ACMN

CANM-CAMRT JOINT ANNUAL CONFERENCE
MARCH 22-24, 2018
VANCOUVER, B.C.

*I **do not have** a financial interest, arrangement or affiliation including receipt of honoraria or expenses with a commercial organization that may have a direct interest in the subject matter of my presentation.*

OUTLINE

1. What is CADTH?

2. Current framework for medical device assessment in Canada
   a. Overview of the life-cycle of health technologies
   b. When and how health technologies assessments are made
   c. Understanding the definition of value

3. Short-comings of traditional approach of HTA & transition to *health technology management*

CADTH

is an independent, not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence about the optimal use of drugs and medical devices.

Our Programs and Services

DRUG REIMBURSEMENT RECOMMENDATIONS

- CADTH Common Drug Review (CDR)
- CADTH pan-Canadian Oncology Drug Review (pCODR)

HEALTH TECHNOLOGY MANAGEMENT PROGRAM

- Rapid Response Service
- Health Technology Assessment Service
- Optimal Use Service
- Environmental Scanning
- Horizon Scanning

OTHER PROGRAMS AND SERVICES

- Scientific Advice

KNOWLEDGE MOBILIZATION AND LIAISON OFFICERS

- Located in jurisdictions across Canada
- Understand the needs and priorities of local decision-makers
- Provide advice and tools to help turn evidence into policy and practice

CADTH

CADTH

was created to build Canada's capacity to use evidence as the basis for sound health care decisions. This strategic imperative remains a cornerstone of our work.

Current framework for medical device assessment in Canada

CADTH

Current framework for medical device assessment in Canada

- Canada is a federal system that is highly decentralized
- Regulatory approval to enter the marketplace is conducted federally by Health Canada
  - Special access/compassionate use
- Once in the market place, funding for medical devices is determined and provided at the provincial/territorial level
  - Single 3rd party payer
- Administration of health care delivery is done regionally within provinces



CADTH

Current framework for medical device assessment in Canada

CADTH

Traditional Health Technology Assessment

When: Life Cycle of a Technology



Funding decisions

- Based on an explicit decision making framework
  - *Comparative* Effectiveness
  - *Comparative* Safety
  - Consistency with social, ethical principles
  - Efficiency
    - **VALUE**
    - **Not synonymous with cost**

Value



- High value health care
  - Positive results (improved patient outcomes, safety, and satisfaction) at a total cost that is *reasonable* and *affordable*

CADTH

Value

- How to calculate "value"?
  - Metric
    - Incremental cost/per unit of health gained
    - ICER
  - Depends on the jurisdiction and health care system
    - Canada – fixed budget

Cost/health gain for each technology



Cost/health gain for each technology




Cost/health gain for each technology
Societal Health Improves
50k-150k
Threshold
Displaced technology
New technology
Funded
Budget
Not Funded
Health care expenditure

Cost-effectiveness Analysis

- Value of a technology is calculated by formal cost-effectiveness analyses
  - Includes all relevant comparators and determines the incremental cost per unit of health gained (ie value)

Ok……but…

- Does an HTA lead to adoption???



Horizon Scanning

HTA/ Optimal Use products

Knowledge mobilization, Implementation support

delisting

CADTH

(Future) Role of CADTH

- Transforming from a **health technology assessment** agency to a **health technology management** agency

PASSIVE vs ***ACTIVE***

ROLE IN DEVICE MANAGEMENT



Horizon Scanning

CADTH

Pre-regulatory

- Horizon Scanning
  - Provide update on products 2-5 years in the pipeline
    - Newsletters
  - Informed from multiple sources including industry
  - Meant to “prepare the system”
    - inform topic selection for larger health technology assessments



HTA/ Optimal Use products

CADTH

Topic Identification and Prioritization



CADTH

Topic Identification and Prioritization

- Prioritization Process
  - Phase I filter:
    - Clinical impact
    - Economic impact
    - Population impact
    - Jurisdictional interest
    - Equity



CADTH

Topic Identification

- Once topics have been ranked by priority, 2-3 per quarter will go forward as HTA

- Detailed Scoping

CADTH Deliberative Framework

- Multi-criteria approach:
  - Relevance and Unmet Need
  - Benefits
  - Harms
  - Patient perspective
  - Economic impact
  - Implementation
  - Legal
  - Ethical
  - Environmental impact

CADTH will produce an evidentiary bundle across these domains

- External expert committee makes recommendations

Process



CADTH

Project Components

- Protocol
  - **“fit for purpose”**
- Science review
  - Clinical systematic review
  - Economic analysis
  - Reviews of additional considerations
    - Ethical, legal, social implications
    - Implementation issues
  - Patient perspectives
- Recommendations

General Timelines



CADTH



Knowledge mobilization, Implementation support

CADTH

Knowledge Mobilization

- Development of key messages based on recommendations and HTA report
  - why there is a gap between the way a technology is used and the evidence
- Early and ongoing identification and engagement of stakeholder groups
  - Partnerships
- Supporting local adaptation

Knowledge Mobilization Tools & Strategies

- Project highlights
- Policy brief
- Optimal Therapy Newsletter
-
-
-
-
- Café Scientifique events

IMPACT



CADTH

Opportunities

- Greater alignment of regulatory and adoption process
  - Use special access as an input for topic selection

- Initiate earlier reimbursement assessments
  - Challenges is quality of evidence
  - Need for reassessments
  - ? Conditional approval

- Implementation
  - Regional hubs
  - Informing value based procurement

- Disinvestment

Summary

- Regulatory and reimbursement landscape for medical devices in Canada remains complex
  - CADTH is transforming from a HTA agency to health technology management

- Opportunities exists to streamline process for selected high impact, disruptive technologies

Connect With Us

@CADTH_ACMTS

linkedin.com/company/cadth

slideshare.net/CADTH-ACMTS

youtube.com/CADTHACMTS

cadth.ca/photoblog

requests@cadth.ca

CADTH